The Role of the Vascular Surgeon in Oncologic Surgery of Abdominal and Pelvic Retroperitoneal Masses
Launched by IRCCS AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA · Jan 29, 2025
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the role of vascular surgeons in the surgical treatment of retroperitoneal tumors, which are abnormal growths found in the area behind the abdominal organs. These tumors can be benign (non-cancerous) or malignant (cancerous), with the majority being malignant. The goal of the surgery is to remove these tumors completely while minimizing risks and complications. The trial aims to see if having a specialized team, including vascular surgeons, can improve the outcomes for patients undergoing this type of surgery.
To be eligible for this trial, participants must be at least 18 years old and have a diagnosed retroperitoneal mass that needs surgical removal. They must also be scheduled for surgery that will involve the assistance of a vascular surgeon. If you join the study, you can expect to receive care from a team of experts and be monitored closely during your treatment. This trial is currently recruiting participants of all genders, and it’s important to understand that, while larger surgeries may carry some risks, the study aims to improve overall success and survival rates for patients with these tumors.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient diagnosed with a retroperitoneal mass involving the abdominal and/or pelvic vascular structures and requiring surgical removal
- • Planned surgical treatment with intra-operative assistance from the vascular surgeon
- • Obtaining informed consent
- • Age 18 years
- Exclusion Criteria:
- • -
About Irccs Azienda Ospedaliero Universitaria Di Bologna
IRCCS Azienda Ospedaliero-Universitaria di Bologna is a prestigious research and healthcare institution in Italy, renowned for its commitment to advancing medical science and patient care through innovative clinical research. As an IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), it integrates clinical practice with scientific research, facilitating the translation of laboratory findings into effective treatment strategies. The institution fosters a multidisciplinary approach, collaborating with various experts to conduct high-quality clinical trials aimed at improving health outcomes across a wide range of medical fields. With a strong emphasis on ethical standards and patient welfare, IRCCS Azienda Ospedaliero-Universitaria di Bologna plays a vital role in shaping the future of medicine through rigorous scientific inquiry and patient-centered care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bologna, Italia, Italy
Patients applied
Trial Officials
Mauro Gargiulo, MD
Principal Investigator
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported